K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma

Robb E. Wilentz, Christine H. Chung, Patrick D J Sturm, Alex Musler, Taylor A. Sohn, G. Johan A Offerhaus, Charles J. Yeo, Ralph H. Hruban, Robbert J C Slebos

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

BACKGROUND. Many patients with carcinoma of the pancreas die because their disease is not detected until late in its course. Methods that detect these cancers earlier will improve patient outcome. Over 80% of pancreatic carcinomas contain mutations in codon 12 of the K-ras gene. Screening duodenal fluid for these mutations may lead to early detection of these cancers and assist in establishing a diagnosis of pancreatic carcinoma. METHODS. Polymerase chain reaction (PCR), with and without restriction enzyme-mediated mutant enrichment, was performed on DNA isolated from duodenal fluid specimens from 61 patients who underwent pancreaticoduodenectomy (Whipple's operation) for either periampullary cancer or a benign condition of the pancreas. Representative sections of pancreas pathology (primary carcinoma, benign tumor, or chronic pancreatitis) from the patients with duodenal fluid specimens containing amplifiable DNA were also analyzed for K-ras mutations. Wild-type and mutant K-ras were detected by hybridization of the PCR products with K-ras codon 12 mutant and wild-type specific probes. RESULTS. Seven of the 61 duodenal fluid specimens contained DNA that did not amplify. Thirteen (24% of the 54 duodenal fluid specimens with amplifiable DNA and 21% of the total of 61 specimens) contained activating point mutations at codon 12 of the K-ras gene. Mutations were detected in 13 of the 51 duodenal fluid specimens from patients with cancer (sensitivity, 25%), whereas mutations were not detected in any of the 9 amplifiable duodenal fluid specimens from patients with benign conditions of the pancreas (specificity, 100%). One duodenal fluid specimen from a patient with adenocarcinoma of the pancreas had two different K-ras mutations. DNA from three of the primary carcinomas did not amplify or was not available. Twenty-nine (69%) of the 42 primary tumors with amplifiable DNA contained K- ras mutations, whereas 3 (30%) of the 10 pancreata with benign conditions harbored mutations. Twenty-two (65%) of 34 ductal adenocarcinomas of the pancreas with amplifiable DNA had K-ras mutations. It is note-worthy that the same mutation was present in both the duodenal fluid and the primary carcinomas of 11 (92%) of the 12 patients who had primary tumors with amplifiable DNA as well as K-ras mutations in their duodenal fluid specimens. CONCLUSIONS. The identification of genetic alterations in cancer-causing genes in duodenal fluid may form the basis for the development of new approaches to the detection of carcinoma of the pancreas. Some pancreata without cancer, however, may also harbor K-ras mutations, potentially limiting the specificity of K-ras-based tests.

Original languageEnglish (US)
Pages (from-to)96-103
Number of pages8
JournalCancer
Volume82
Issue number1
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Mutation
Pancreas
DNA
Carcinoma
Codon
Neoplasms
ras Genes
Pancreatic Carcinoma
Adenocarcinoma
Polymerase Chain Reaction
Pancreaticoduodenectomy
Neoplasm Genes
Chronic Pancreatitis
Pancreatic Neoplasms
Early Detection of Cancer
Point Mutation
Pathology
Enzymes

Keywords

  • Duodenal fluid
  • K-ras mutations
  • Pancreatic carcinoma
  • Whipple's operation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wilentz, R. E., Chung, C. H., Sturm, P. D. J., Musler, A., Sohn, T. A., Offerhaus, G. J. A., ... Slebos, R. J. C. (1998). K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer, 82(1), 96-103. https://doi.org/10.1002/(SICI)1097-0142(19980101)82:1<96::AID-CNCR11>3.0.CO;2-8

K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. / Wilentz, Robb E.; Chung, Christine H.; Sturm, Patrick D J; Musler, Alex; Sohn, Taylor A.; Offerhaus, G. Johan A; Yeo, Charles J.; Hruban, Ralph H.; Slebos, Robbert J C.

In: Cancer, Vol. 82, No. 1, 01.01.1998, p. 96-103.

Research output: Contribution to journalArticle

Wilentz, RE, Chung, CH, Sturm, PDJ, Musler, A, Sohn, TA, Offerhaus, GJA, Yeo, CJ, Hruban, RH & Slebos, RJC 1998, 'K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma', Cancer, vol. 82, no. 1, pp. 96-103. https://doi.org/10.1002/(SICI)1097-0142(19980101)82:1<96::AID-CNCR11>3.0.CO;2-8
Wilentz, Robb E. ; Chung, Christine H. ; Sturm, Patrick D J ; Musler, Alex ; Sohn, Taylor A. ; Offerhaus, G. Johan A ; Yeo, Charles J. ; Hruban, Ralph H. ; Slebos, Robbert J C. / K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. In: Cancer. 1998 ; Vol. 82, No. 1. pp. 96-103.
@article{fda6fb3152ea47e6899d582453cdd6fc,
title = "K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma",
abstract = "BACKGROUND. Many patients with carcinoma of the pancreas die because their disease is not detected until late in its course. Methods that detect these cancers earlier will improve patient outcome. Over 80{\%} of pancreatic carcinomas contain mutations in codon 12 of the K-ras gene. Screening duodenal fluid for these mutations may lead to early detection of these cancers and assist in establishing a diagnosis of pancreatic carcinoma. METHODS. Polymerase chain reaction (PCR), with and without restriction enzyme-mediated mutant enrichment, was performed on DNA isolated from duodenal fluid specimens from 61 patients who underwent pancreaticoduodenectomy (Whipple's operation) for either periampullary cancer or a benign condition of the pancreas. Representative sections of pancreas pathology (primary carcinoma, benign tumor, or chronic pancreatitis) from the patients with duodenal fluid specimens containing amplifiable DNA were also analyzed for K-ras mutations. Wild-type and mutant K-ras were detected by hybridization of the PCR products with K-ras codon 12 mutant and wild-type specific probes. RESULTS. Seven of the 61 duodenal fluid specimens contained DNA that did not amplify. Thirteen (24{\%} of the 54 duodenal fluid specimens with amplifiable DNA and 21{\%} of the total of 61 specimens) contained activating point mutations at codon 12 of the K-ras gene. Mutations were detected in 13 of the 51 duodenal fluid specimens from patients with cancer (sensitivity, 25{\%}), whereas mutations were not detected in any of the 9 amplifiable duodenal fluid specimens from patients with benign conditions of the pancreas (specificity, 100{\%}). One duodenal fluid specimen from a patient with adenocarcinoma of the pancreas had two different K-ras mutations. DNA from three of the primary carcinomas did not amplify or was not available. Twenty-nine (69{\%}) of the 42 primary tumors with amplifiable DNA contained K- ras mutations, whereas 3 (30{\%}) of the 10 pancreata with benign conditions harbored mutations. Twenty-two (65{\%}) of 34 ductal adenocarcinomas of the pancreas with amplifiable DNA had K-ras mutations. It is note-worthy that the same mutation was present in both the duodenal fluid and the primary carcinomas of 11 (92{\%}) of the 12 patients who had primary tumors with amplifiable DNA as well as K-ras mutations in their duodenal fluid specimens. CONCLUSIONS. The identification of genetic alterations in cancer-causing genes in duodenal fluid may form the basis for the development of new approaches to the detection of carcinoma of the pancreas. Some pancreata without cancer, however, may also harbor K-ras mutations, potentially limiting the specificity of K-ras-based tests.",
keywords = "Duodenal fluid, K-ras mutations, Pancreatic carcinoma, Whipple's operation",
author = "Wilentz, {Robb E.} and Chung, {Christine H.} and Sturm, {Patrick D J} and Alex Musler and Sohn, {Taylor A.} and Offerhaus, {G. Johan A} and Yeo, {Charles J.} and Hruban, {Ralph H.} and Slebos, {Robbert J C}",
year = "1998",
month = "1",
day = "1",
doi = "10.1002/(SICI)1097-0142(19980101)82:1<96::AID-CNCR11>3.0.CO;2-8",
language = "English (US)",
volume = "82",
pages = "96--103",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma

AU - Wilentz, Robb E.

AU - Chung, Christine H.

AU - Sturm, Patrick D J

AU - Musler, Alex

AU - Sohn, Taylor A.

AU - Offerhaus, G. Johan A

AU - Yeo, Charles J.

AU - Hruban, Ralph H.

AU - Slebos, Robbert J C

PY - 1998/1/1

Y1 - 1998/1/1

N2 - BACKGROUND. Many patients with carcinoma of the pancreas die because their disease is not detected until late in its course. Methods that detect these cancers earlier will improve patient outcome. Over 80% of pancreatic carcinomas contain mutations in codon 12 of the K-ras gene. Screening duodenal fluid for these mutations may lead to early detection of these cancers and assist in establishing a diagnosis of pancreatic carcinoma. METHODS. Polymerase chain reaction (PCR), with and without restriction enzyme-mediated mutant enrichment, was performed on DNA isolated from duodenal fluid specimens from 61 patients who underwent pancreaticoduodenectomy (Whipple's operation) for either periampullary cancer or a benign condition of the pancreas. Representative sections of pancreas pathology (primary carcinoma, benign tumor, or chronic pancreatitis) from the patients with duodenal fluid specimens containing amplifiable DNA were also analyzed for K-ras mutations. Wild-type and mutant K-ras were detected by hybridization of the PCR products with K-ras codon 12 mutant and wild-type specific probes. RESULTS. Seven of the 61 duodenal fluid specimens contained DNA that did not amplify. Thirteen (24% of the 54 duodenal fluid specimens with amplifiable DNA and 21% of the total of 61 specimens) contained activating point mutations at codon 12 of the K-ras gene. Mutations were detected in 13 of the 51 duodenal fluid specimens from patients with cancer (sensitivity, 25%), whereas mutations were not detected in any of the 9 amplifiable duodenal fluid specimens from patients with benign conditions of the pancreas (specificity, 100%). One duodenal fluid specimen from a patient with adenocarcinoma of the pancreas had two different K-ras mutations. DNA from three of the primary carcinomas did not amplify or was not available. Twenty-nine (69%) of the 42 primary tumors with amplifiable DNA contained K- ras mutations, whereas 3 (30%) of the 10 pancreata with benign conditions harbored mutations. Twenty-two (65%) of 34 ductal adenocarcinomas of the pancreas with amplifiable DNA had K-ras mutations. It is note-worthy that the same mutation was present in both the duodenal fluid and the primary carcinomas of 11 (92%) of the 12 patients who had primary tumors with amplifiable DNA as well as K-ras mutations in their duodenal fluid specimens. CONCLUSIONS. The identification of genetic alterations in cancer-causing genes in duodenal fluid may form the basis for the development of new approaches to the detection of carcinoma of the pancreas. Some pancreata without cancer, however, may also harbor K-ras mutations, potentially limiting the specificity of K-ras-based tests.

AB - BACKGROUND. Many patients with carcinoma of the pancreas die because their disease is not detected until late in its course. Methods that detect these cancers earlier will improve patient outcome. Over 80% of pancreatic carcinomas contain mutations in codon 12 of the K-ras gene. Screening duodenal fluid for these mutations may lead to early detection of these cancers and assist in establishing a diagnosis of pancreatic carcinoma. METHODS. Polymerase chain reaction (PCR), with and without restriction enzyme-mediated mutant enrichment, was performed on DNA isolated from duodenal fluid specimens from 61 patients who underwent pancreaticoduodenectomy (Whipple's operation) for either periampullary cancer or a benign condition of the pancreas. Representative sections of pancreas pathology (primary carcinoma, benign tumor, or chronic pancreatitis) from the patients with duodenal fluid specimens containing amplifiable DNA were also analyzed for K-ras mutations. Wild-type and mutant K-ras were detected by hybridization of the PCR products with K-ras codon 12 mutant and wild-type specific probes. RESULTS. Seven of the 61 duodenal fluid specimens contained DNA that did not amplify. Thirteen (24% of the 54 duodenal fluid specimens with amplifiable DNA and 21% of the total of 61 specimens) contained activating point mutations at codon 12 of the K-ras gene. Mutations were detected in 13 of the 51 duodenal fluid specimens from patients with cancer (sensitivity, 25%), whereas mutations were not detected in any of the 9 amplifiable duodenal fluid specimens from patients with benign conditions of the pancreas (specificity, 100%). One duodenal fluid specimen from a patient with adenocarcinoma of the pancreas had two different K-ras mutations. DNA from three of the primary carcinomas did not amplify or was not available. Twenty-nine (69%) of the 42 primary tumors with amplifiable DNA contained K- ras mutations, whereas 3 (30%) of the 10 pancreata with benign conditions harbored mutations. Twenty-two (65%) of 34 ductal adenocarcinomas of the pancreas with amplifiable DNA had K-ras mutations. It is note-worthy that the same mutation was present in both the duodenal fluid and the primary carcinomas of 11 (92%) of the 12 patients who had primary tumors with amplifiable DNA as well as K-ras mutations in their duodenal fluid specimens. CONCLUSIONS. The identification of genetic alterations in cancer-causing genes in duodenal fluid may form the basis for the development of new approaches to the detection of carcinoma of the pancreas. Some pancreata without cancer, however, may also harbor K-ras mutations, potentially limiting the specificity of K-ras-based tests.

KW - Duodenal fluid

KW - K-ras mutations

KW - Pancreatic carcinoma

KW - Whipple's operation

UR - http://www.scopus.com/inward/record.url?scp=0031893736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031893736&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980101)82:1<96::AID-CNCR11>3.0.CO;2-8

DO - 10.1002/(SICI)1097-0142(19980101)82:1<96::AID-CNCR11>3.0.CO;2-8

M3 - Article

C2 - 9428484

AN - SCOPUS:0031893736

VL - 82

SP - 96

EP - 103

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -